MENLO PARK, Calif., May 29 /PRNewswire/ -- Acclarent, Inc., a leading medical technology company dedicated to designing, developing and commercializing devices that address conditions affecting the ear, nose and throat today announced that it won the "Red Herring 100 North America" award. The Red Herring editorial team deploys a detailed process to whittle down a pool of 1,200 eligible, promising companies to decide on the top 100 winners of this important North American award. Evaluations are made on both quantitative and qualitative criteria, such as financial performance, innovation, management, global strategy, and ecosystem integration. Alex Vieux, CEO of Red Herring, presented the award to the winning companies in San Diego on May 14, 2009.
"Acclarent will cure and help millions of Americans over the years. This represents innovation excellence at its best led by pristine investors and a seasoned team. It fully deserves its place within the Red Herring 100 North America," said Mr. Vieux.
"Being recognized by Red Herring as one of the most promising private companies in North America is a tremendous accomplishment. On behalf of the 300 deserving employees at Acclarent, I would like to thank Red Herring for this prestigious award," said Bill Facteau, President and CEO of Acclarent, Inc.
About Red Herring
Red Herring is a global media company, which unites the world's best high technology innovators, venture investors and business decision makers in a variety of forums: a leading innovation magazine, an online daily technology news service, technology newsletters and major events for technology leaders around the globe. Red Herring provides an insider's access to the global innovation economy, featuring unparalleled insights on the emerging technologies driving the economy. More information about Red Herring is available online at www.redherring.com.
Acclarent is a medical technology company dedicated to the development of innovative products providing new technologies to further meet the needs of ENT patients.
Acclarent's initial focus is on achieving the goals of sinus surgery with novel, endoscopic, catheter-based tools - Balloon Sinuplasty(TM) devices. Through the Balloon Sinuplasty(TM) technology and our Relieva(R) product portfolio we offer ENT patients alternatives to conventional endoscopic surgical approaches. Through our core technologies and commitment to innovation, Acclarent will continue to advance novel devices in all areas of ENT. Acclarent markets and sells its products worldwide and has been used by thousands of physicians globally. For more information about Acclarent, visit www.Acclarent.com.
|SOURCE Red Herring|
Copyright©2009 PR Newswire.
All rights reserved